# Magnesium Migraine Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/magnesium-migraine-meta-analysis-evidence-review
Category: evidence-review
Summary: Magnesium Migraine Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are system
Last reviewed: 2026-05-21
Reviewed by: Migaku Evidence Review
# Magnesium Migraine Meta-analysis: What the Evidence Says

## Quick Answer

Magnesium Migraine Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF) | systematic review | 1 | 2026-04-17 | 10.1186/s10194-026-02350-x |
| Magnesium supplementation for migraine prophylaxis | narrative review | 3 | 2025-11-11 | 10.1002/14651858.CD016307 |

## What The Sources Report

- Increased estradiol levels during pregnancy and breastfeeding are hypothesized to enhance susceptibility to Cortical Spreading Depression (CSD), thereby triggering or worsening aura attacks. [Braca Simone (2026); evidence level 1]
- Evidence regarding therapies such as CGRP-targeted monoclonal antibodies (mAbs), gepants (CGRP receptor antagonists), and triptans (serotonin 5-HT1B/1D receptor agonists) is mixed, with reported sex differences in efficacy, recurrence, and adverse events. [Braca Simone (2026); evidence level 1]
- Hormonal shifts during breastfeeding might also affect migraine occurrence, although the evidence is not definitive. [Rodriguez Juan Pablo (2025); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For magnesium migraine meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Braca Simone (2026). Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF). DOI: 10.1186/s10194-026-02350-x. PMCID: PMC13126917. PMID: 41998499. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13126917/
- Rodriguez Juan Pablo (2025). Magnesium supplementation for migraine prophylaxis. DOI: 10.1002/14651858.CD016307. PMCID: PMC12604082. PMID: 41216917. License: https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Attribution-Non-Commercial Licence This is an open a.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12604082/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.